Jim Cramer: Johnson & Johnson Stock Poised for Growth
CNBC TelevisionJanuary 15, 20261 min826 views
6 connections·7 entities in this video→Johnson & Johnson's Recent Performance
- 💡 Johnson & Johnson (J&J) is highlighted as a top-performing stock, considered the second-best after Eli Lilly.
- 🚀 The company has experienced a remarkable move in its stock price, overcoming previous challenges.
Overcoming Past Challenges
- ⚠️ J&J was previously suppressed by talc lawsuits, but has decided not to fight them, which has been a positive development.
- 📉 The company has also divested from Kenview and is shedding its orthopedics business, which is seen as a commodity market.
Future Growth Drivers
- 📈 J&J is focusing on its fastest-growing oncological portfolio and other innovative ventures.
- 💰 The stock is considered attractive, selling at 19 times earnings, suggesting significant upside potential.
- 🎯 The company is pure-play pharma and is experiencing rapid growth in this sector.
Legal and Market Outlook
- ⚖️ J&J is no longer engaging in class-action lawsuits for ovarian cancer cases and is not losing these cases.
- 📊 The company's performance is expected to be strong, with analysts anticipating another good year ahead.
Knowledge graph7 entities · 6 connections
How they connect
An interactive map of every person, idea, and reference from this conversation. Hover to trace connections, click to explore.
Hover · drag to explore
7 entities
Chapters1 moments
Key Moments
Transcript7 segments
Full Transcript
Topics10 themes
What’s Discussed
Johnson & JohnsonJ&J StockJim CramerMad DashTalc LawsuitsOncological PortfolioOrthopedicsPharmaStock PerformanceEarnings Multiple
Smart Objects7 · 6 links
Companies· 5
Events· 2